JP Morgan Chase
ODT

JP Morgan Chase’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

JP Morgan Chase’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-58,683
Closed -$171K – 7224
2021
Q3 		$171K Sell
58,683
-75,950
-56% -$253K ﹤0.01% 5317
2021
Q2 		$470K Buy
134,633
+60,484
+82% +$208K ﹤0.01% 4736
2021
Q1 		$254K Buy
74,149
+17,430
+31% +$329K ﹤0.01% 5054
2020
Q4 		$1.09M Sell
56,719
-5,952
-9% -$91.9K ﹤0.01% 3907
2020
Q3 		$909K Buy
62,671
+54,963
+713% +$1.56M ﹤0.01% 3696
2020
Q2 		$326K Sell
7,708
-19,879
-72% -$643K ﹤0.01% 4051
2020
Q1 		$762K Buy
27,587
+15,732
+133% +$459K ﹤0.01% 3590
2019
Q4 		$385K Buy
11,855
+8,011
+208% +$248K ﹤0.01% 4369
2019
Q3 		$100K Sell
3,844
-10,249
-73% -$343K ﹤0.01% 4906
2019
Q2 		$495K Sell
14,093
-25,965
-65% -$622K ﹤0.01% 4243
2019
Q1 		$886K Buy
40,058
+25,641
+178% +$448K ﹤0.01% 3881
2018
Q4 		$203K Buy
14,417
+4,007
+38% +$62.4K ﹤0.01% 4599
2018
Q3 		$202K Buy
10,410
+2,302
+28% +$46.9K ﹤0.01% 4686
2018
Q2 		$179K Buy
8,108
+6,746
+495% +$157K ﹤0.01% 4607
2018
Q1 		$29K Buy
+1,362
New +$32.1K ﹤0.01% 4985

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

JP Morgan Chase's ODT Position: Q4 2021 in Review

JP Morgan Chase sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 58,683 shares — an estimated $171K sold.

JP Morgan Chase first reported a position in ODT in Q1 2018 and held it in 15 quarters. The position peaked at $1.09M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • JP Morgan Chase reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 58,683 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $171K.
  • JP Morgan Chase first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • JP Morgan Chase's Odonate Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.